Hay existencias
GROW Blend: Una mezcla de investigación de doble vía que combina CJC 1295 sin DAC (5 mg) e Ipamorelina (5 mg).
$145.00
Hay existencias
GROW Blend es una formulación de investigación de dos componentes que combina CJC 1295 sin DAC, un análogo de la hormona liberadora de la hormona del crecimiento, e Ipamorelina, un secretagogo selectivo de la hormona del crecimiento.
Se suministra como una mezcla de grado de investigación para laboratorios que estudian la fisiología del eje hipotalámico-hipofisario, la liberación pulsátil de la hormona del crecimiento y la señalización metabólica y de IGF-1 posterior.
CJC 1295 sin DAC es un fragmento modificado de GHRH diseñado para interactuar con el receptor de la hormona liberadora de la hormona del crecimiento con un perfil farmacocinético que favorece pulsos de hormona del crecimiento de estilo fisiológico en lugar de una estimulación continua. La Ipamorelina es un agonista selectivo del receptor de grelina que actúa en el receptor secretagogo de la hormona del crecimiento (GHSR) para promover la liberación de la hormona del crecimiento con una actividad comparativamente limitada sobre otras hormonas hipofisarias en perfiles preclínicos. En sistemas experimentales, la combinación de un análogo de GHRH y un agonista de GHSR se utiliza para explorar efectos cooperativos en los somatotropos hipofisarios. GROW Blend permite a los investigadores examinar cómo la estimulación de doble vía moldea la amplitud y frecuencia de los pulsos endógenos de la hormona del crecimiento y mapear los cambios consecuentes en los niveles de IGF-1, marcadores de composición corporal y lecturas endocrinas relacionadas bajo condiciones controladas. Al proporcionar ambos péptidos en una formulación de proporción fija, esta mezcla está posicionada para estudios que requieren una coadministración consistente de CJC 1295 sin DAC e Ipamorelina en ensayos basados en células y modelos in vivo.
GROW Blend está destinado exclusivamente a experimentos in vitro, preparaciones ex vivo y otras aplicaciones de investigación de laboratorio controladas, incluidos estudios en animales realizados bajo la supervisión adecuada. Los usos típicos incluyen la caracterización del eje de la hormona del crecimiento, trabajos de farmacología de receptores, estudios de la función hipofisaria y modelos metabólicos y de composición corporal que dependen de la modulación endógena de la hormona del crecimiento.
No está destinado para uso humano o veterinario.
No está destinado para el diagnóstico, tratamiento, cura, prevención o mitigación de ninguna enfermedad, problema de rendimiento o preocupación antienvejecimiento.
No es un medicamento, alimento, suplemento dietético, cosmético o dispositivo médico.
Combinación fija de CJC 1295 sin DAC e Ipamorelina para una investigación coordinada del eje de la hormona del crecimiento. Actúa sobre las vías de GHRH y GHSR para apoyar la investigación de la liberación pulsátil fisiológica de la hormona del crecimiento. Reduce la complejidad de la preparación de péptidos separados cuando se requiere una administración dual en diseños experimentales. Fabricado bajo condiciones controladas con verificación analítica de la identidad y pureza de cada componente y la proporción de la mezcla.
GROW Blend combines CJC 1295 no DAC a growth hormone releasing hormone analogue with Ipamorelin a ghrelin receptor agonist.
It is used in controlled models to study coordinated activation of the hypothalamic pituitary axis growth hormone pulse physiology and downstream metabolic effects.
The sections below summarise how dual GHRH and GHSR pathway activation is applied in preclinical research. All observations are model specific and do not imply any performance or anti aging claims.
CJC 1295 no DAC is a modified GHRH analogue engineered to support pulsatile growth hormone release patterns rather than flat continuous elevation. Ipamorelin is a selective GHSR agonist with relatively selective action on growth hormone secretion compared with other pituitary hormones. In the normal growth hormone axis GHRH neurons in the hypothalamus release GHRH which engages GHRH receptors on somatotroph cells. Separately ghrelin from the stomach and other tissues engages GHSR to enhance growth hormone release. GROW Blend enables research into how coordinated stimulation of both pathways influences the amplitude frequency and stability of endogenous growth hormone pulses in animal models and ex vivo pituitary systems. These studies help map how the dual input system maintains physiologic growth hormone dynamics compared with single pathway activation or non physiologic continuous stimulation.
In ex vivo pituitary tissue and isolated somatotroph preparations GROW Blend is used to characterise dose response relationships and receptor cross talk.
Researchers measure growth hormone release kinetics into the incubation medium intracellular cAMP and calcium dynamics in somatotrophs somatostatin feedback effects under dual stimulation. The goal is to understand how GHRH and GHSR signaling converge at the level of the somatotroph to control hormone release in a physiologically relevant manner. Comparisons with single peptide arms and saline controls help isolate the contribution of each pathway and test for synergy.
Growth hormone exerts many effects through IGF 1 which is produced primarily by the liver in response to growth hormone stimulation. Animal studies using GROW Blend typically measure circulating IGF 1 levels at multiple time points hepatic IGF 1 gene expression IGF 1 signaling marker phosphorylation in target tissues.
These measurements establish whether the dual pathway stimulation produces growth hormone pulses sufficient to drive robust IGF 1 production and whether IGF 1 responses differ from single peptide paradigms.
A major application of growth hormone axis research is understanding how changes in growth hormone and IGF 1 influence skeletal muscle and fat distribution.
GROW Blend is used in models that track muscle mass by imaging or direct tissue analysis skeletal muscle protein synthesis markers muscle strength measurements in functional tests lean mass preservation during metabolic challenges. In rodent studies CJC 1295 no DAC plus Ipamorelin is deployed to examine how dual GHRH and GHSR activation supports muscle anabolism compared with control or single peptide treated groups. These models also track markers of protein breakdown to evaluate net changes in muscle turnover.
Growth hormone is lipolytic meaning it promotes fat mobilisation and oxidation. GROW Blend studies often measure total body fat content and regional distribution visceral versus subcutaneous free fatty acid levels and glycerol mobilisation markers hepatic triglyceride content markers of adipose tissue inflammation and metabolic dysfunction.
Dual pathway activation is explored to see whether it produces greater shifts in fat utilisation than single peptide approaches and whether these shifts occur without triggering compensatory metabolic adaptations.
Growth hormone and IGF 1 are important regulators of bone turnover and strength. Animal models track bone density and mineral content by imaging serum markers of bone formation and resorption mechanical properties of harvested bones osteoblast and osteoclast activity markers. GROW Blend is used to investigate whether coordinated growth hormone axis stimulation produces additive effects on bone anabolism and whether dual pathway activation offers advantages over single route stimulation in models of bone loss or injury repair.
Beyond growth hormone and IGF 1 the growth hormone axis intersects with broader metabolic regulation. GROW Blend studies often include measurement of glucose homeostasis and insulin sensitivity indices lipid profiles including cholesterol and triglycerides thyroid hormone levels cortisol and other glucocorticoids glucagon and other counter regulatory hormones. These integrated profiles help define how dual GHRH and GHSR activation affects whole body metabolism rather than looking at isolated growth hormone effects.
A key experimental distinction is between peptides that support physiologic pulsatile growth hormone release and those that create sustained elevation.
CJC 1295 no DAC is specifically designed to preserve pulsatility. GROW Blend studies frequently compare animals dosed with CJC 1295 no DAC plus Ipamorelin against groups receiving DAC containing variants or continuous growth hormone infusions. Endpoints measure quality of life related outcomes recovery from metabolic stress and long term tolerance. This work aims to test whether preserving natural growth hormone rhythms produces better functional and metabolic outcomes than imposing artificial continuous elevation.
Growth hormone is known to support recovery from injury infection and metabolic stress. GROW Blend is used in models where animals undergo controlled insults such as
thermal or mechanical injury sepsis or endotoxin challenge fasting or metabolic depletion forced exercise or overtraining paradigms. Researchers measure how GROW Blend treated groups compare to controls on metrics of inflammatory resolution wound healing mitochondrial recovery and return to baseline physiology. These studies position dual growth hormone axis activation as a potential tool for understanding physiologic stress responses.
While Ipamorelin is relatively selective for GHSR it has modest activity at other receptors. GROW Blend research includes experiments to define selectivity profiles and to distinguish growth hormone mediated effects from any direct peptide actions on non somatotroph cells.
Typical approaches include
pharmacologic receptor blockade to isolate GHSR versus GHRH contributions use of receptor deficient animal models to attribute effects to specific pathways tissue specific measurements to localise where dual stimulation produces its primary effects.
Across laboratories GROW Blend is commonly used in growth hormone axis physiology and pituitary function studies pulsatile versus continuous growth hormone release comparison models body composition and lean mass research bone health and skeletal remodeling investigations metabolic flexibility and whole body energy balance studies
recovery and stress resilience paradigms long term tolerance and side effect profiling of dual pathway agents. In all these contexts GROW Blend is a mechanistic research tool not a finished performance or anti aging product.
All findings summarised here arise from in vitro systems animal models and limited translational studies under defined protocols. They are provided solely to inform qualified researchers about how GROW Blend is applied in growth hormone axis research. These observations do not show or imply that GROW Blend or its components are safe or effective for any human or veterinary indication. They are not dosing instructions medical advice or guidance for muscle building fat loss performance enhancement or anti aging use. GROW Blend is intended strictly for laboratory research applications. It is not for human or veterinary use and must not be used for diagnosis treatment cure prevention or mitigation of any disease or condition.
Rango de precios: desde $50.00 hasta $95.00
BPC 157: Un pentadecapéptido sintético utilizado en modelos de laboratorio para investigar la angiogénesis, la migración de fibroblastos y la integridad de la barrera mucosa.
$325.00
KLOW Blend: Formulación de investigación diseñada para estudiar los efectos convergentes de BPC 157 (10 mg), TB 500 (10 mg), KPV (10 mg) y GHK-Cu (50 mg).
$150.00
Tesamorelina: Un análogo de GHRH de 44 aminoácidos utilizado para investigar la regulación del eje de la hormona del crecimiento, la adiposidad visceral y las interacciones neuroendocrino-metabólicas.
$285.00
GLOW Blend: Una formulación de investigación consolidada de BPC 157 (10 mg), TB 500 (10 mg) y GHK-Cu (50 mg).
